Growth ⏱ Half-life: Several days due to PEG protection from enzymatic degradation. Preclinical

PEG-MGF

PEGylated Mechano Growth Factor

Updated March 15, 2026

Evidence at a Glance

Regulatory statusPreclinical
Pegylated IGF-1 splice variant (MGF); no human trials, research-use-only
Human evidenceNone
Animal evidenceLimited

PEG-MGF is a pegylated form of the IGF-1 splice variant MGF studied only in cell and rodent muscle-repair models, with no published human clinical trials at any phase.

What the research does not support

  • It has never been tested in a published human clinical trial, so no dosing, efficacy, or safety data in people exists.
  • Muscle satellite-cell activation has only been shown in vitro and in animals; it does not translate to proven muscle growth in humans.
  • It is not an approved drug or supplement and is sold strictly for laboratory research use.
  • PEGylation extends its half-life but does not confer any demonstrated clinical benefit or safety margin.
Half-Life
Several days due to PEG protection from enzymatic degradation.
Mol. Weight
~5000 g/mol (with PEG)

What is PEG-MGF?

PEG-MGF is the stabilized, long-acting version of Mechano Growth Factor created by attaching a polyethylene glycol chain to the peptide. This modification solves MGF’s primary limitation — its extremely short half-life.

Research Applications

Systemic muscle repair signaling, extended satellite cell activation, body composition research, and recovery protocols.

Dosage Information (Research Use)

Research protocols: 200 mcg subcutaneously, 2-3 times per week. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution.

Half-Life & Pharmacokinetics

Several days due to PEG protection from enzymatic degradation.

Reported Observations in Literature

Similar profile to MGF. Limited human safety data.

Key Research References

  • Goldspink G. “Mechanical signals, IGF-I gene splicing, and muscle adaptation.” Physiology. 2005

How PEG-MGF Works

PEG-MGF adds a polyethylene glycol (PEG) chain to the MGF peptide, protecting it from rapid enzymatic degradation. This extends the half-life from minutes to several days, enabling systemic distribution rather than purely local action.

Research Findings

Allows for less frequent dosing than non-PEG MGF. Can be administered subcutaneously rather than requiring local injection.

Dosage & Administration

Research protocols: 200 mcg subcutaneously, 2-3 times per week. Research use only.

Safety & Side Effects

Similar profile to MGF. Limited human safety data.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence PEGylated IGF-1Ec C-terminal peptide
Molecular Weight ~5000 g/mol (with PEG)
Half-Life Several days due to PEG protection from enzymatic degradation.
Available Sizes 2mg, 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C.

Key Research References

  • Goldspink G. "Mechanical signals, IGF-I gene splicing, and muscle adaptation." Physiology. 2005

Related Peptides

View all →
Follistatin 315
Growth
Muscle-selective follistatin isoform with less systemic activity than Follistatin 344, reducing off-target endocrine effects.
View Profile →
MK-677
Growth
Non-peptide oral ghrelin mimetic that provides sustained GH and IGF-1 elevation over 24 hours with once-daily oral dosing.
View Profile →
CJC-1295
Growth
Growth hormone releasing hormone analog that stimulates pulsatile GH secretion for sustained elevation of growth hormone and IGF-1.
View Profile → Buy Now